Home / 2019 / May

Monthly Archives: May 2019

WillScot to Participate at the Stifel 2019 Cross Sector Insight Conference

BALTIMORE, May 31, 2019 (GLOBE NEWSWIRE) — WillScot Corporation (“WillScot”) (Nasdaq: WSC), the specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that Brad Soultz, President and Chief Executive Officer, and Matt Jacobsen, Vice President Finance, will be presenting and hosting one-on-one meetings at the Stifel 2019 Cross Sector Insight Conference at The InterContinental Boston, in Boston, MA, on Monday, June 10, 2019.  The presentation will take place at 4:10 p.m. EDT.

About WillScot Corporation
Headquartered in Baltimore, Maryland, WillScot is the public holding company for the Williams Scotsman family of companies. WillScot trades on the Nasdaq stock exchange under the ticker symbol “WSC,” and is the specialty rental services market leader providing innovative modular space and portable storage solutions across North America. WillScot is the modular space supplier of choice for the construction, education, health care, government, retail, commercial, transportation, security and energy sectors. With over half a century of innovative history, organic growth and strategic acquisitions, WillScot serves a broad customer base from over 120 locations throughout the United States, Canada and Mexico, with a fleet of approximately 160,000 modular space and portable storage units.

Additional Information and Where to Find It

Additional information about WillScot can be found on its investor relations website: https://investors.willscot.com

Contact Information

Investor Inquiries:

Mark Barbalato
investors@willscot.com

Media Inquiries:

Scott Junk
scott.junk@willscot.com

Helsinn Group Announces Upcoming Presentation of Phase 3b data of NEPA (fosnetupitant / palonosetron) IV at ASCO 2019

Helsinn Group Announces Upcoming Presentation of Phase 3b data of NEPA (fosnetupitant / palonosetron) IV at ASCO 2019

  • The NEPA IV formulation was evaluated for safety in the AC setting.

Lugano, Switzerland, May 31, 2019 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that the data on the intravenous (IV) formulation of NEPA (Akynzeo®) will be presented as poster at the American Society of Clinical Oncology (ASCO) Congress in June 2019 on the poster session Symptoms and Survivorship.

NEPA (Akynzeo®) is the first and only 5-HT3 and NK1 receptor combination approved for the prevention of chemotherapy induced acute and delayed nausea and vomiting. A single dose of Akynzeo given with dexamethasone has been shown to prevent chemotherapy induced nausea and vomiting for 5 days.

This randomized, multinational, double-blind, stratified (by age and region) Phase 3b study in chemotherapy-naïve patients, evaluated the safety of a single 30-minute infusion of NEPA IV agent (fosnetupitant 235 mg, a neurokinin 1 receptor antagonist (NK1 RA), and palonosetron 0.25 mg, a serotonin-3 receptor antagonist (5-HT3 RA)) in breast cancer patients receiving anthracycline/cyclophosphamide (AC) chemotherapy. 402 patients received either NEPA IV (200 patients) or NEPA oral (202 patients), in combination with oral dexamethasone on day 1. Safety was assessed primarily by treatment-emergent adverse events (TEAEs).

The AE profiles were similar for the two treatment groups1. No infusion site reactions related to NEPA IV occurred, and no anaphylactic reactions were reported for either formulation. NEPA IV does not require a surfactant, emulsifier, or solubility enhancer, and contains no allergenic excipients.

Lee S. Schwartzberg, Hematology & Oncology, West Cancer Center, Germantown, TN, the author of the study, commented: “These data demonstrate that NEPA IV has a similar safety profile to NEPA administered orally. We are encouraged by the similar profiles, and particularly by the lack of infusion site reactions.

Sergio Cantoreggi, Helsinn Group Chief Scientific Officer and Group Head of R&D, added: At Helsinn, our key focus is on the quality of life and well-being of the patients. Tolerability can be a significant concern for intravenously administered antiemetics especially in AC. We look forward to discussing these new NEPA IV safety data at ASCO.

  • Title: Safety of intravenous (IV) NEPA and oral NEPA for prevention of CINV in patients (pts) with breast cancer (BC) receiving anthracycline/cyclophosphamide (AC) chemotherapy (CT)
  • Author: L. Schwartzberg, D. Voisin, G. Rizzi, K. Patel, M. Aapro
  • Abstract number: 11594
  • Session title: Symptoms and Survivorship
  • Date, time and location: Monday, June 3, 2019, 1:15 PM-4:15 PM, at Hall A

ASCO 2019 will be held from May 31 to June 4, 2019 in Chicago, US. Further details can be found here: https://www.asco.org/meetings

About Akynzeo® (NEPA)

INDICATION

AKYNZEO® (netupitant 300mg/palonosetron 0.5mg) capsules was approved October 2014 in the United States and is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.

AKYNZEO® (fosnetupitant 235mg/palonosetron 0.25) for injection was approved April 2018 in the United States and is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy.

Limitations of Use

  • AKYNZEO for injection has not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy.

AKYNZEO is a combination of palonosetron, a serotonin-3 (5-HT3) receptor antagonist, and netupitant or fosnetupitant, substance P/neurokinin-1 (NK-1) receptor antagonists: palonosetron prevents nausea and vomiting during the acute phase and netupitant/fosnetupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

  • Hypersensitivity reactions, including anaphylaxis, have been reported in patients receiving palonosetron, one of the components of AKYNZEO, with or without known hypersensitivity to other 5-HT3 receptor antagonists.
  • Serotonin syndrome has been reported with 5-HT3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs.  Serotonin syndrome can be life threatening. Symptoms associated with serotonin syndrome may include the following combination of signs and symptoms: mental status changes, autonomic instability, neuromuscular symptoms, seizures, and gastrointestinal symptoms. Patients should be monitored for the emergence of serotonin syndrome, and if symptoms occur, discontinue AKYNZEO and initiate supportive treatment. Patients should be informed of the increased risk of serotonin syndrome, especially if AKYNZEO is used concomitantly with other serotonergic drugs.

Adverse Reactions

  • Most common adverse reactions for AKYNZEO capsules and injection: headache, asthenia, dyspepsia, fatigue, constipation and erythema

Drug Interactions

  • Use with caution in patients receiving concomitant medications primarily metabolized by CYP3A4. The plasma concentrations of CYP3A4 substrates can increase when co-administered with AKYNZEO. The inhibitory effect on CYP3A4 can last for multiple days
    • Dexamethasone doses should be reduced when given with AKYNZEO. A more than two-fold increase in the systemic exposure of dexamethasone was observed 4 days after a single dose of netupitant or a single infusion of fosnetupitant
    • Consider the potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) when administering with AKYNZEO. When administered with netupitant, the systemic exposure to midazolam was significantly increased
  • Avoid concomitant use of AKYNZEO in patients on chronic use of a strong CYP3A4 inducer such as rifampin as this may decrease the efficacy of AKYNZEO

Use in Specific Populations

  • Avoid use of AKYNZEO in patients with severe hepatic impairment, severe renal impairment, or end-stage renal disease
  • Avoid use in pregnancy, limited data is available, may cause fetal harm.

For more information about AKYNZEO® please see the full Prescribing Information or visit www.AKYNZEO.com

About the Helsinn Group

Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, the U.S., Monaco and China, as well as a product presence in approximately 190 countries globally.

To learn more about Helsinn Group please visit www.helsinn.com

For more information:

Helsinn Group Media Contact

Paola Bonvicini

Group Head of Communication

Lugano, Switzerland

Tel: +41 (0) 91 985 21 21

Info-hhc@helsinn.com

For more information, please visit www.helsinn.com and follow us on TwitterLinkedIn and Vimeo


1 The most common treatment-related AEs during the entire study were headache (2.5% IV NEPA, 3.4% oral NEPA), dizziness (2.5% in both groups), fatigue (2.0% in both groups) and constipation (2.5% IV NEPA, 1.0% oral NEPA); all other treatment-related AEs occurred in < 2% of patients.

Constellation Brands to Report First Quarter Fiscal 2020 Financial Results; Host Conference Call June 28, 2019

VICTOR, N.Y., May 30, 2019 (GLOBE NEWSWIRE) — Constellation Brands, Inc. (NYSE: STZ and STZ.B), a leading beverage alcohol company, announced today it will report financial results for its fiscal first quarter ended May 31, 2019, on Friday, June 28, 2019, before the open of the U.S. markets. A conference call to discuss the financial results and outlook will be hosted by President and Chief Executive Officer Bill Newlands and Executive Vice President and Chief Financial Officer David Klein at 10:30 a.m. EDT, June 28, 2019.

The conference call can be accessed by dialing +1-877-673-1771 and entering conference identification number 1699493, beginning at 10:20 a.m. EDT. A live, listen-only webcast of the conference call will be available on the company’s website, www.cbrands.com, under the Investors/Events & Presentations section. When the call begins, financial information discussed on the conference call, and a reconciliation of reported (GAAP) financial measures with comparable or non-GAAP financial measures, will also be available on the company’s website under Investors and by selecting Reporting. For anyone unable to participate in the conference call, a replay will be available on the company’s website.

About Constellation Brands
Constellation Brands (NYSE: STZ and STZ.B), a Fortune 500® company, is a leading international producer and marketer of beer, wine and spirits with operations in the U.S., Mexico, New Zealand, Italy and Canada. Constellation is the No. 3 beer company in the U.S. with high-end, iconic imported beer brands such as the Corona and Modelo brand families and Pacifico. Its high-quality, wine and spirits brands include the Robert Mondavi and The Prisoner Wine Company brand families, Kim Crawford, Ruffino, Meiomi and SVEDKA Vodka. The company’s portfolio also includes a collection of highly-rated, wine brands such as SIMI and Mount Veeder Winery wine brands, High West Whiskey and Casa Noble Tequila, as well as new wine innovations such as Cooper & Thief and Spoken Barrel.

Based in Victor, N.Y., the company believes that industry leadership involves a commitment to brand building, our trade partners, the environment, our investors and to consumers around the world who choose our products when celebrating big moments or enjoying quiet ones. Since its founding in 1945, Constellation’s ability to see, meet and stay ahead of shifting consumer preferences and trends across total beverage alcohol has fueled our success and made us the No. 1 growth contributor in beverage alcohol in the U.S.

To learn more, follow us on Twitter @cbrands and visit www.cbrands.com.

MEDIA CONTACTS INVESTOR RELATIONS CONTACTS
Mike McGrew   773-251-4934 michael.mcgrew@cbrands.com Patty Yahn-Urlaub  585-678-7483  patty.yahn-urlaub@cbrands.com
Amy Martin   585-678-7141 amy.martin@cbrands.com Bob Czudak  585-678-7170  bob.czudak@cbrands.com
Tom Conaway  585-678-7503  thomas.conaway@cbrands.com

A downloadable PDF copy of this news release enhanced with multimedia links can be found here: http://ml.globenewswire.com/Resource/Download/1a232d65-6144-4626-a04b-e843ccd0383a

Multi-code electronics joins UMW’s High Value Manufacturing Park as tenant

KUALA LUMPUR, The UMW group’s High Value Manufacturing (HVM) Park in Serendah, Selangor, has attracted automotive electronics parts company Multi-Code Electronics Industries (M) Bhd (MCEIB) as a tenant.

UMW Corporation Bhd said its wholly-owned subsidiary UMW Development Sdn Bhd (UMWD) inked an agreement with MCE Holding Bhd’s unit MCEIB today for the development of 3.34 hectares in the park as part of the phase one development.

According to MCE Holding’s announcement to Bursa Malaysia, MCEIB acquired the land for RM14.37 million to expand its manufacturing facilities. It currently has facilities in Johor Bahru and Shah Alam.

“The addition of MCEIB also highlights the growing number of advanced manufacturing companies setting up in UMW High Value Manufacturing Park, home to UMW Aerospace Malaysia’s first Tier 1 fan case supplier to Rolls-Royce and T7 Kilgour metal treatment plant,” UMW said in its statement.

MCEIB is the manufacturer and supplier of automotive electronics and mechatronic parts for the Malaysian and overseas markets and is one of Malaysia’s leading original equipment manufacturer suppliers in the automotive industry.

UMWD director property development Eric Chew said UMW’s pioneering industrial park was designed to be the centrepiece of Malaysia’s rapidly evolving high value manufacturing industry.

The 348.4 hectare site offers the latest in Industry 4.0-enabled innovation and advanced manufacturing infrastructure, he said.

At UMW HVM Park, our commitment does not stop at providing pioneering advanced manufacturing technologies but also steadfast support to the businesses which call the facility home, said Chew.

Through end-to-end facilitation in a rapidly growing ecosystem, UMWD was confident that the park would continue to accelerate expansion of Malaysia’s vital high value manufacturing industry, he added.

Source: BERNAMA (News Agency)

Pembinaan Mitrajaya, Medini Development terminates contract worth RM159 mln

KUALA LUMPUR, Mitrajaya Holdings Bhd’s (MHB) wholly-owned unit, Pembinaan Mitrajaya Sdn Bhd (PMJ) and Medini Development Sdn Bhd (MDSB) have mutually agreed to terminate a contract worth RM159.38 million.

In a filing with Bursa Malaysia today, MHB said the termination of the contract for superstructure works on an office tower development in Mukim Pulai, Johor Bahru would reduce the company’s order book by RM112.2 million.

“Part of the works for this contract has started and has been recognised in the financial statement of the group for the year ended Dec 31, 2018,” it said.

According to the filing, MDSB had informed PMJ that after careful consideration, the company had decided to put the development of the project on hold until market condition stabilises.

“The group will not be able to recognise the potential earnings in the financial year ending Dec 31, 2019 upon the mutual termination,” it said, adding that there would be no other financial impact.

Source: BERNAMA (News Agency)

News In Brief: May 31 2019

SHOPEE, a leading e-commerce platform in Southeast Asia and Taiwan has recorded over 95 per cent of mobile orders in the first quarter of 2019 (Q1).

“As e-commerce in Malaysia is set to achieve annual growth of 20 per cent in 2020, online shopping is also growing in tandem,” it said in a statement today,

Marketing lead Shopee Malaysia Marianne Chuo said Shopee was committed to delivering a social and engaging online shopping experience and would continue doing so by developing more innovative new features.

“We have introduced features like Shopee Live and Shopee Quiz to entertain users with richer new media content and as a result, we see that users are spending more time on Shopee as they tune in regularly to our live streams and quizzes that make online shopping more interactive, Chuo added.

Source: BERNAMA (News Agency)

T to raise RM470 mln sukuk for energy projects

KUALA LUMPUR, Telekosang Hydro One Sdn Bhd (T) has appointed MIDF Amanah Investment Bank Bhd as the principal adviser, lead arranger and joint lead manager for its proposed Islamic medium term notes issuance of up to RM470 million.

MIDF Amanah has also been appointed as principal adviser, lead arranger and lead manager for T’s proposed junior bonds issuance of up to RM120 million in nominal value.

Today, MIDF Amanah has lodged the Lodgement Kits for the Telekosang ASEAN Green sustainable and responsible investment (SRI) Sukuk and the Telekosang ASEAN Green Junior Bonds with the Securities Commission Malaysia.

We are delighted to be principal adviser, lead arranger and joint lead manager for this greenfield mini-hydro green SRI sukuk.

It shows that renewable energy and particularly run-of-river hydro is bankable and that the Malaysian capital markets can finance a more environmentally friendly future for the generations to come, said MIDF group managing director Datuk Charon Mokhzani in a statement today.

The Telekosang ASEAN Green SRI Sukuk and the Telekosang ASEAN Green Junior Bonds have tenures of up to 18 years and 20 years, respectively.

T and Telekosang Hydro Two Sdn Bhd have been granted feed-in approvals on Oct 26, 2017, from Sustainable Energy Development Authority Malaysia (SEDA) for the development of 24 MW and 16 MW small hydropower plants respectively, using run-of-river scheme, located in Tenom, Sabah.

The companies have also been granted with the renewable energy power purchase agreements relating to the projects with Sabah Electricity Sdn Bhd on March 28, 2019.

The issuance proceeds from the Telekosang ASEAN Green SRI Sukuk and the Telekosang ASEAN Green Junior Bonds will be mainly used to part finance the projects.

Source: BERNAMA (News Agency)